47. Clinical benefit table: Orthovisc. Dichotomous outcome measures.

Study	Time	Treatment	Outcome	No. improved	No. of pts.	Risk (%)	Risk difference	NNT
Brandt 2001	14‐26 wk	E: Orthovisc	WOMAC pain (number of patients improved)	61	66	92	5	20
		C: Saline		60	69	87
Brandt 2001	14‐26 wk	E: Orthovisc	WOMAC pain greater than 5 unit improvement	38	66	58	17	5.9
		C: Saline		28	69	41
Tekeoglu 1998	1‐4 wk	E: Orthovisc	Patient global (number of patients good/very good)	10	20	50	‐10	10
		C: Betamethasone		12	20	60
Tekeoglu 1998	5‐13 wk	E: Orthovisc	Patient global (number of patients good/very good)	15	20	75	35	2.9
		C: Betamethasone		8	20	40
Kalay 1997	5‐13 wk	E: Orthovisc + PT	Number of patients rating treatment effective/very effective	19	20	95	35	2.9
		C: PT		12	20	60
Guler 1996	5‐13 wk	E: Orthovisc	Number of patients rating treatment effective/very effective	11	15	73	40	2.5
		C: Saline		5	15	33